Table 1.

miRNAs targeting Zeb1 and Zeb2.

miRNA	Targets	Cancer subtype	Expression changes	Effect	References	p53 regulation
miR-142-3p	Zeb1	N/S	↓	Downregulated in BC. Reduced expression is associated with tumor size and lymph node metastasis	98	Downregulated by mutant p53
				Attenuates breast CSC characteristics	99
miR-96-183 (miR183-96-182 cluster)	Zeb1	N/S	↑	High expression is a prognostic biomarker for BC, and correlated with local relapse, distant metastasis, and poor clinical outcomes	100	Induced by p53
		LA	↓	Downregulated in LA BC-induced overexpression of miR-183 inhibited migration of breast cancer cells	101
			↑	miR-96 was upregulated in BC, enhanced proliferation, migration, and tumor growth	102
miR-141 (miR-200 family)	Zeb1 Zeb2	N/S	↑	The level was significantly higher in the blood of patients with stage I–III, lymph node metastasis, and Her2 negative tumors. Low expression of miR-141 was associated with unfavorable overall survival	103	Induced by p53
		TN	­	Overexpression promotes migratory and invasive ability of TN BC cells	104
		TN	­	Ectopic expression enhanced brain metastatic colonization	105
		N/S	↑	High level is a marker of circulating tumor cells presence and metastasis	106
miR-200a-200b-200c (miR-200 family)	Zeb1 Zeb2	TN	­	High levels block angiogenesis in tumor	107	Induced by p53
		MBC	↑	High levels are associated with metaplastic breast cancer and upregulated Zeb1, Zeb2, Snail, and Slug	108
		N/S	↑	High levels are markers of circulating tumor cells presence and metastasis	106
		TN	↓	Low level is a characteristic of triple-negative BC subtype	109
		LA, LB	↓	Low expression indicated reduced survival in PR-positive BC cases	110
		HER2+, TN	↑	High expression in tumors and increased content in blood were associated with shortened relapse-free survival of patients with in PR-negative BC	103
miR-429 (miR-200 family)	Zeb1 Zeb2	TN	↓	Low level is a marker of BC compared to normal breast tissue. TN breast cancer is characterized by the lowest miR-429 compared to other BC types	111	Induced by p53
		TN	-	Upregulated in TN BC (MDA-MB-231 and MDA-MB-468) treated with δ-tocotrienol and induces apoptosis	112
		TN	­	High expression suppresses metastasis formation and migration of MDA-MB-231cells	113
miR-33a	Zeb1	TN, MTC	↓	Downregulated in TN breast cancer	114	Suppresses p53 in hematopoetic stem cells
		N/S	–	Expression is negatively associated with lymph node metastasis and clinical stage, expression lower in metastatic cell lines	65
miR-655	Zeb1	TN	↓	Reduced expression in triple-negative BC compared to normal tissue and other cancer types. Lower expression is associated with higher lymph-node status	115
miR-153	Zeb2	LA, TN	­	Ectopic expression inhibited tumor growth and impair the migration and invasion of breast cancer cells	116
		TN	­	Expression was induced by Mifepristone and resulted in suppressed tumor growth of the TN BC cell lines and patient-derived xenografts	117
miR-192	Zeb2	N/S	↓	Decreased in BC tissues	118	Induced by p53
		N/S	↓	Decreased in BC tissues and known to inhibit proliferation	119
miR-215	Zeb2	N/S	↓	Downregulated in BC and targets Sox9 lower levels contributed to unfavorable prognosis	120	Induced by p53, activates p53
		N/S	↓	Low expression correlated with higher tumor grade, Her2 positive status, lymph node metastasis, and low expression led to lower 5-year DSS (Disease-specific survival)	121
miR-218	Zeb2	N/S	↓	Lower expression of mir-218 is associated with a higher tumor grade, lymph node metastasis and poor prognosis	122
miR-338p	Zeb2	N/S	↓	Downregulated in BC, expression is inversely correlated with lymph node metastasis and TNM stage	123
miR-101	Zeb1, Zeb2	MTC	↓	Downregulated in metastatic BC cells, expression varies amongst different subtypes	124	Induced by p53
miR-205	Zeb1, Zeb2	N/S	↓	Downregulated in BC	125	Induced by p53
		N/S	↓	Lowest levels in basal-like and invasive TN breast cancers, inhibits CSC-like phenotype by downregulating ITGA5	126
miR-340	Zeb1, Zeb2	N/S	­	BC patients with high miR-340 expression unlikely to achieve pathologic complete response	127	Stabilizes p53
		TN	­	Inhibits BC progression and metastasis	128
miR-448	Zeb1, Zeb2	N/S	↓	Downregulation is observed in BC patients with chemotherapy-induced EMT	129
miR-508-3p	Zeb1, Zeb2	TN	↓	Expression was decreased in TN BC. Lower miR-508-3p expression significantly associated with lymph node metastasis and distant metastasis	130

BC breast cancer, LA luminal A subtype, LB luminal B subtype, TN triple-negative (basal-like) subtype, HER2+ HER2-positive subtype, MBC metaplastic breast cancer, MTC metastatic breast carcinomas, N/S subtype is not specified, FBT familiar breast tumors, ER estrogen receptor, PR progesterone receptor, CSC cancer stem cells.